アデノ随伴ウイルスベクター/AAVベクター市場：AAVベースの遺伝子治療とAAV製造にフォーカス：治療の種類（遺伝子増強療法、免疫療法、その他）、使用される遺伝子導入方法の種類（生体外および生体内）、標的治療領域（遺伝子疾患、血液疾患、感染症、代謝疾患、応用分野（遺伝子治療、細胞治療、ワクチン）、事業規模（前臨床、臨床、商業）、地域（北米、欧州、アジア太平洋、中東・アフリカ、中南米、その他の地域）：業界動向と世界予測、2022-2035年

Adeno-Associated Viral Vectors / AAV Vector Market: Focus on AAV Based Gene Therapy and AAV Manufacturing by Type of Therapy (Gene Augmentation, Immunotherapy and Others), Type of Gene Delivery Method Used (Ex vivo and In vivo), Target Therapeutic Area (Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Muscle Disorders, Ophthalmic Disorders, Neurological Disorders and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Scale of Operation (Preclinical, Clinical and Commercial) and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

世界のAAVベクター市場は2022年に19億米ドルに達すると予測され、予測期間2022-2035年のCAGRは14%で成長すると予測されている。近年、細胞レベルで病気の原因を狙い撃ちする可能性を活用した遺伝子治療への関... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年7月1日	US$4,799 シングルユーザライセンスライセンス・価格情報注文方法はこちら	250	英語

サマリー

世界のAAVベクター市場は2022年に19億米ドルに達すると予測され、予測期間2022-2035年のCAGRは14%で成長すると予測されている。

近年、細胞レベルで病気の原因を狙い撃ちする可能性を活用した遺伝子治療への関心と需要が急増している。現在、285以上の遺伝子治療薬がさまざまな臨床開発段階で評価されている。このような需要の高まりは多額の資金流入につながり、遺伝子治療開発企業は2021年だけで100億米ドルを超える資金を調達している。このような急成長を背景に、革新的な送達方法に対するニーズが高まっている。利用可能な遺伝子導入ベクターの中で、アデノ随伴ウイルスベクター（AAV）は非常に効率的であることが証明されている。現在までに6つのAAVベースの遺伝子治療が承認されており、そのうち5つが米国FDAによって承認され、最新のものは2023年6月に承認された。同時に、多数のAAVベースの治療法がさまざまな臨床試験で評価中である。近年、AAVベースの遺伝子治療を評価する臨床試験は30％という驚異的な伸びを示しており、今後3年以内に50以上の臨床試験が終了すると予想されている。

この需要の高まりに対応するため、AAVベースの遺伝子治療の開発と製造に注力する企業が世界中で100社近く出現している。これらの企業の多くは、アデノ随伴ウイルスベクターや関連療法を小規模から大規模まで様々な事業規模で製造できる高度なAAV技術プラットフォームを提供している。AAVベースの遺伝子治療開発企業の市場は、予測期間中に力強い成長が見込まれる。この軌跡は、AAV製造企業や高度なAAV技術プラットフォームのプロバイダーからの共同支援によって推進されるでしょう。安全で効果的な遺伝子治療デリバリーオプションとしてAAVベクターが広く認知され採用されていることが、この有望な市場展望を後押しする主要因となっています。

レポート範囲
 当レポートでは、AAVベクター市場を分析し、治療タイプ、遺伝子導入方法、治療ターゲット、用途、事業規模、地域などの要因を検証しています。
 市場成長の促進要因、阻害要因、機会、課題などを評価します。
 主要市場プレイヤーの潜在的な利点、障壁、競争環境の評価を提供します。
 主要6地域にわたる市場セグメントの収益予測を提示しています。
 簡潔な概要で、アデノ随伴ウイルスベクター市場の現状と中長期的に予想される進化を概説。
 アデノ随伴ウイルスベクターの構造設計、ライフサイクル・ダイナミクス、応用を包括的に論じ、その固有の利点と課題の分析で結んでいる。
 AAVベースの遺伝子治療市場の詳細な調査には、開発段階、治療領域、標的遺伝子、治療タイプ、送達方法、投与経路、特効薬指定が含まれる。
 AAV製造に携わる企業の調査には、設立の詳細、企業規模、本社、製造製品、施設所在地、製造タイプ、事業規模、応用分野が含まれます。
 AAV市場に従事する企業が提供する技術を、種類、事業規模、応用分野、著名な市場プレイヤーの特定ごとに分類してレビュー。
 上市済みおよび開発段階にある AAV ベースの遺伝子治療薬の詳細なプロフィールは、開発スケジュール、現況、作用機序、関連 AAV 技術、特許ポートフォリオ、用法・用量、製造の詳細、開発企業情報を網羅しています。
 AAV製造企業の概要、財務実績（入手可能な場合）、ベクター製造能力、将来展望を含む、厳選されたAAV製造企業のプロフィールを集計。
 サプライヤーの強み、製造能力、サービス範囲、企業規模を考慮した 4 次元バブル表現を用いて、地域横断的な AAV 製造における企業の競争力を分析。
 サプライヤーの強み、技術目的、事業規模、応用分野を考慮した AAV ベクター技術プラットフォームの詳細評価。
 治験登録年、フェーズ、治療領域、地域、スポンサー、治療部位、登録患者集団などのパラメータを評価した、完了済み、進行中、および計画中の臨床試験の調査。
 AAV製造に焦点を当てた2017年以降の提携およびパートナーシップの評価、パートナーシップの種類、治療領域、パートナーの種類、地域分布の調査。
 開発者の強み、製品ポートフォリオ、治療フォーカス、パイプラインの強みを考慮した、AAVおよび遺伝子治療製品メーカーとのパートナーシップの可能性に関する洞察。
 特許の種類、公開年、地域的適用可能性、特許出願における業界リーダー、特許評価など、2017年以降にAAVベースの療法に対して出願／付与された特許の包括的分析。
 AAVベースの遺伝子治療を開発する新興企業を分析し、その開発段階、特許、パートナーシップ、主要指標を評価。
 AAVベースの遺伝子治療開発企業が、自社製造か受託製造機関（CMO）のどちらを採用するかを決定する際に考慮すべき要素を、中小企業、中堅企業、大企業のパラメータを考慮しながら詳細に分析。

主要市場企業
 アベオナ・セラピューティクス
 アルデブロン（ダナハーが買収）
 オックスフォード・バイオメディカ
 サノフィ（CEPiA、サノフィ・パスツール、ジェンザイム）
 WuXi AppTec
 YPOSKESI

ページTOPに戻る

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Vectors
3.2.1. Viral Vectors
3.2.1.1. Adenovirus Vectors
3.2.1.2. Adeno-Associated Viral Vectors
3.2.1.3. Lentivirus Vectors
3.2.1.4. Retrovirus Vectors
3.2.1.5. Other Viral Vectors
3.2.1.5.1. Alphavirus
3.2.1.5.2. Foamy Virus
3.2.1.5.3. Simian Virus
3.2.1.5.4. Vaccinia Virus
3.2.1.5.5. Chimeric Viral Vectors
3.2.1.5.6. Herpes Simplex Virus
3.2.1.5.7. Sendai Virus
3.2.2. Non-Viral Vectors
3.2.2.1. Plasmid DNA
3.2.2.2. Oligonucleotides
3.2.2.3. Liposomes, Lipoplexes, and Polyplexes
3.2.2.4. Other Non-Viral Vectors
3.3. Adeno-Associated Viral Vectors
3.3.1. Structure and Design
3.3.2. Adeno-Associated Viral Vector Life Cycle
3.3.3. Applications of Adeno-Associated Viral Vectors
3.3.3.1. Gene Therapy
3.3.3.2. Vaccination
3.3.4. Advantages of Adeno-Associated Viral Vectors
3.3.5. Challenges Related to Adeno-Associated Viral Vectors
3.4. Concluding Remarks
4. AAV BASED GENE THERAPY: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. AAV Based Gene Therapy: Overall Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area(s)
4.2.3. Analysis by Type of Gene / Molecule Targeted
4.2.4. Analysis by Type of Therapy
4.2.5. Analysis by Type of Gene Delivery Method Used
4.2.6. Analysis by Route of Administration
4.3. AAV Based Gene Therapy Candidates: Special Designations
4.3.1. Analysis by Special Designation(s) Awarded
4.4. AAV Based Gene Therapy: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. AAV Based Gene Therapy: Leading Developers
5. AAV MANUFACTURING COMPANIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. AAV Manufacturing Companies: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product(s) Manufactured
5.2.5. Analysis by Location of Vector Manufacturing Facilities
5.2.6. Analysis by Type of Manufacturer and Company Size
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Location of Headquarters and Scale of Operation
5.2.9. Analysis by Application Area(s)
6. AAV TECHNOLOGY: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. AAV Technology
6.2.1. Analysis by Type of Technology
6.2.2. Analysis by Scale of Operation
6.2.3. Analysis by Application Area(s)
6.2.4. Analysis by Therapeutic Area
6.3. AAV Technology: List of Developers
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters
6.3.5. AAV Technology: Leading Developers
7. DRUG PROFILES
7.1. Chapter Overview
7.2. Marketed AAV Based Gene Therapies
7.2.1. LUXTURNA® (Spark Therapeutics)
7.2.1.1. Company Overview
7.2.1.2. Development Timeline
7.2.1.3. Mechanism of Action
7.2.1.4. Target Indication(s)
7.2.1.5. Current Status of Development
7.2.1.6. Manufacturing, Dosage and Sales
7.2.2. ZOLGENSMA® (Novartis)
7.2.2.1. Company Overview
7.2.2.2. Development Timeline
7.2.2.3. Mechanism of Action
7.2.2.4. Target Indication(s)
7.2.2.5. Current Status of Development
7.2.2.6. Manufacturing, Dosage and Sales
7.3.1. HEMGENIX® (CSL Behring / UniQure)
7.3.1.1. Company Overview
7.3.1.2. Development Timeline
7.3.1.3. Mechanism of Action
7.3.1.4. Target Indication(s)
7.3.1.5. Current Status of Development
7.3.1.6. Manufacturing, Dosage and Sales
7.4.1. ROCTAVIAN® (BioMarin Pharmaceuticals)
7.4.1.1. Company Overview
7.4.1.2. Development Timeline
7.4.1.3. Mechanism of Action
7.4.1.4. Target Indication(s)
7.4.1.5. Current Status of Development
7.4.1.6. Manufacturing, Dosage and Sales
7.5.1. ELEVIDYS® (Sarepta Therapeutics)
7.5.1.1. Company Overview
7.5.1.2. Development Timeline
7.5.1.3. Mechanism of Action
7.5.1.4. Target Indication(s)
7.5.1.5. Current Status of Development
7.5.1.6. Manufacturing, Dosage and Sales
7.6.1. UPSTAZA® (PTC Therapeutics)
7.6.1.1. Company Overview
7.6.1.2. Development Timeline
7.6.1.3. Mechanism of Action
7.6.1.4. Target Indication(s)
7.6.1.5. Current Status of Development
7.6.1.6. Manufacturing, Dosage and Sales
7.6. Late Stage (Phase II/III and Above) Gene Therapies
7.6.1. AGTC 501: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.2. LYS-SAF302: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.3. NFS-01: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.4. RGX-314: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.5. OAV-101: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.6. PF-06838435: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.7. PF-06939926: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.8. PF-07055480: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
7.6.9. SPK-8011: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Abeona Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. AAV Manufacturing Related Capabilities
8.2.4. Recent Developments and Future Outlook
8.3 Aldevron (Acquired by Danaher)
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. AAV Manufacturing Related Capabilities
8.3.4. Recent Developments and Future Outlook
8.4 Oxford BioMedica
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. AAV Manufacturing Related Capabilities
8.4.4. Recent Developments and Future Outlook
8.5 Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. AAV Manufacturing Related Capabilities
8.5.4. Recent Developments and Future Outlook
8.6. WuXi AppTec
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. AAV Manufacturing Related Capabilities
8.6.4. Recent Developments and Future Outlook
8.7. YPOSKESI
8.7.1. Company Overview
8.7.2. AAV Manufacturing Related Capabilities
8.7.3. Recent Developments and Future Outlook
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. AAV Manufacturing Companies: In-house Manufacturers
9.3.1. Players based in North America
9.3.2. Players based in Europe
9.4. AAV Manufacturing Companies: Contract Manufacturing Organizations
9.4.1. Players based in North America
9.4.2. Players based in Europe
9.4.3. Players based in Asia-Pacific
9.5. AAV Manufacturing Companies: Both In-House and Contract Manufacturing Organizations
9.5.1. Players based in North America
9.5.2. Players based in Europe
9.5.3. Players based in Asia-Pacific
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology and Key Parameters
10.3. AAV Technology Platforms
10.3.1. AAV Technology Platforms Developed by Companies based in North America
10.3.2. AAV Technology Platforms Developed by Companies based in Europe and Asia-Pacific
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. AAV Based Gene Therapy: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
11.3.3. Analysis by Trial Phase and Enrolled Patient Population
11.3.4. Analysis by Trial Status
11.3.5. Analysis by Study Design
11.3.6. Analysis by Therapeutic Area
11.3.7. Analysis by Target Disease Indication
11.3.8. Analysis by Type of Sponsor / Collaborator
11.3.9. Leading Industry Players: Analysis by Number of Registered Trials
11.3.10. Regional Analysis
11.3.10.1. Analysis by Number of Registered Trials
11.3.10.2. Analysis by Enrolled Patient Population
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. AAV Based Gene Therapy: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year of Partnership and Type of Partner
12.3.4. Analysis by Type of Partnership and Type of Partner
12.3.5. Analysis by Therapeutic Area
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Regional Analysis
12.3.7.1. Intercontinental and Intracontinental Agreements
12.4. AAV Manufacturing Companies: List of Partnerships and Collaborations
12.4.1. Analysis by Year of Partnership
12.4.2. Analysis by Type of Partnership
12.4.3. Analysis by Year of Partnership and Type of Partner
12.4.4. Analysis by Type of Partnership and Type of Partner
12.4.5. Analysis by Therapeutic Area
12.4.6. Most Active Players: Analysis by Number of Partnerships
12.4.7. Regional Analysis
12.4.7.1. Intercontinental and Intracontinental Agreements
13. STRATEGIC PARTNER ANALYSIS
13.1. Chapter Overview
13.2. AAV Manufacturing Companies: Potential Strategic Partners
13.2.1. Methodology and Key Parameters
13.2.2. AAV Manufacturing Companies: Strategic Partner Analysis
13.2.2.1. Most Likely Partners
13.2.2.2. Likely Partners
13.2.2.3. Less Likely Partners
13.2.2.4. Least Likely Partners
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Adeno-Associated Viral Vectors: Patent Analysis
14.3.1. Analysis by Publication Year
14.3.2. Analysis by Annual Patent Application(s)
14.3.3. Analysis by Annual Granted Patents
14.3.4. Analysis by Geography
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.4. Adeno Associated Viral Vector Based Market: Patent Benchmarking
14.4.1. Analysis by Patent Characteristics
14.5. Adeno-Associated Viral Vectors: Patent Valuation
14.6. Leading Patents: Analysis by Number of Citations
15. START-UP HEALTH INDEXING
15.1. Chapter Overview
15.2. Start-ups Developing Adeno-Associated Viral Vectors
15.2.1. Analysis by Location of Headquarters
15.3. Benchmarking of Start-ups
15.3.1. Analysis by Pipeline Strength
15.3.2. Analysis by Pipeline Maturity
15.3.3. Analysis by Indication Diversity
15.3.4. Analysis by Number of Patents
15.3.5. Analysis by Partnership Activity
15.3.6. Start-ups Health Indexing: Roots Analysis Perspective
16. OUTSOURCING: GO / NO-GO FRAMEWORK
16.1. Chapter Overview
16.2. Outsourcing: Go / No-Go Framework
16.3. AAV Based Gene Therapy Developers Outsourcing: Go / No-Go Framework
16.3.1. Key Parameters and Assumptions
16.3.2. Methodology
16.3.3. Results and Interpretations
16.3.3.1. Small Companies
16.3.3.2. Mid-sized Companies
16.3.3.3. Large Companies
17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Methodology and Key Assumptions
17.3. AAV Based Gene Therapy Market, 2022-2035
17.3.1. AAV Based Gene Therapy Market: Distribution by Therapeutic Area
17.3.2. AAV Based Gene Therapy Market: Distribution by Type of Therapy
17.3.3. AAV Based Gene Therapy Market: Distribution by Type of Gene Delivery Method Used
17.3.4. AAV Based Gene Therapy Market: Distribution by Therapeutic Area
17.3.5. AAV Based Gene Therapy Market: Distribution by Route of Administration
17.3.6. AAV Based Gene Therapy Market: Distribution by Therapeutic Area
17.3.7. AAV Based Gene Therapy Market: Distribution by Geography
17.3.8. AAV Based Gene Therapy Market, 2022-2035: Individual Product Sales Forecast
17.3.8.1. LUXTURNA
17.3.8.1.1. Target Patient Population
17.3.8.1.2. Sales Forecast
17.3.8.1.3. Net Present Value
17.3.8.1.4. Value Creation Analysis
17.3.8.2. ZOLGENSMA
17.3.8.2.1. Target Patient Population
17.3.8.2.2. Sales Forecast
17.3.8.2.3. Net Present Value
17.3.8.2.4. Value Creation Analysis
17.3.8.3. HEMGENIX
17.3.8.3.1. Target Patient Population
17.3.8.3.2. Sales Forecast
17.3.8.3.3. Net Present Value
17.3.8.3.4. Value Creation Analysis
17.3.8.4. ROCTAVIAN
17.3.8.4.1. Target Patient Population
17.3.8.4.2. Sales Forecast
17.3.8.4.3. Net Present Value
17.3.8.4.4. Value Creation Analysis
17.3.8.5. UPSTAZA
17.3.8.5.1. Target Patient Population
17.3.8.5.2. Sales Forecast
17.3.8.5.3. Net Present Value
17.3.8.5.4. Value Creation Analysis
17.3.8.6. ELEVIDYS
17.3.8.6.1. Target Patient Population
17.3.8.6.2. Sales Forecast
17.3.8.6.3. Net Present Value
17.3.8.6.4. Value Creation Analysis
17.3.8.7. AGTC 501
17.3.8.7.1. Target Patient Population
17.3.8.7.2. Sales Forecast
17.3.8.7.3. Net Present Value
17.3.8.7.4. Value Creation Analysis
17.3.8.8. LYS-SAF302
17.3.8.8.1. Target Patient Population
17.3.8.8.2. Sales Forecast
17.3.8.8.3. Net Present Value
17.3.8.8.4. Value Creation Analysis
17.3.8.9. NFS-01
17.3.8.9.1. Target Patient Population
17.3.8.9.2. Sales Forecast
17.3.8.9.3. Net Present Value
17.3.8.9.4. Value Creation Analysis
17.3.8.10. OAV-101
17.3.8.10.1. Target Patient Population
17.3.8.10.2. Sales Forecast
17.3.8.10.3. Net Present Value
17.3.8.10.4. Value Creation Analysis
17.3.8.11. PF-06838435
17.3.8.11.1. Target Patient Population
17.3.8.11.2. Sales Forecast
17.3.8.11.3. Net Present Value
17.3.8.11.4. Value Creation Analysis
17.3.8.12. PF-06939926
17.3.8.12.1. Target Patient Population
17.3.8.12.2. Sales Forecast
17.3.8.12.3. Net Present Value
17.3.8.12.4. Value Creation Analysis
17.3.8.13. PF-07055480
17.3.8.13.1. Target Patient Population
17.3.8.13.2. Sales Forecast
17.3.8.13.3. Net Present Value
17.3.8.13.4. Value Creation Analysis
17.3.8.14. RGX-314
17.3.8.14.1. Target Patient Population
17.3.8.14.2. Sales Forecast
17.3.8.14.3. Net Present Value
17.3.8.14.4. Value Creation Analysis
17.3.8.15. SPK-8011
17.3.8.15.1. Target Patient Population
17.3.8.15.2. Sales Forecast
17.3.8.15.3. Net Present Value
17.3.8.15.4. Value Creation Analysis
17.4. AAV Manufacturing Market, 2022-2035
17.4.1. AAV Manufacturing Market, 2022-2035: Distribution by Phase of Development
17.4.2. AAV Manufacturing Market, 2022-2035: Distribution by Therapeutic Area
17.4.3. AAV Manufacturing Market, 2022-2035: Distribution by Application Area
17.4.4. AAV Manufacturing Market, 2022-2035: Distribution by Key Geographical Regions
17.5 Current and Future Market Opportunity for Commercial Products
17.5.1. AAV Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
17.5.2. AAV Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
17.5.3. AAV Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
17.6. Current and Future Market Opportunity for Clinical Candidates
17.6.1. AAV Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
17.6.2. AAV Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
17.6.3. AAV Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
17.7. Current and Future Market Opportunity for Preclinical Candidates
17.7.1. AAV Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
17.7.2. AAV Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
17.7.3. AAV Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
18. CONCLUDING REMARKS
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Boston College
19.2.1. Organization Snapshot
19.2.2. Interview Transcript: Abhishek Chatterjee, Professor
19.3. University of Florida
19.3.1. Organization Snapshot
19.3.2. Interview Transcript: Arun Srivastava, Professor of Genetics and Chief of Division of Cellular & Molecular Therapy
19.4. Andelyn Biosciences
19.4.1. Organization Snapshot
19.4.2. Interview Transcript: Adam Lauber, Chief Financial Officer
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

Table of Contents

Summary

The global AAV vector market is expected to reach USD 1.9 billion in 2022 and is anticipated to grow at a CAGR of 14% during the forecast period 2022-2035

The surge in interest and demand for gene therapies, leveraging their potential to target disease causes at a cellular level, has been significant in recent years. Currently, more than 285 gene therapies are under evaluation across different clinical development stages. This growing demand has led to substantial capital influx, with gene therapy developers raising over USD 10 billion in 2021 alone. In this burgeoning landscape, there is an increased need for innovative delivery methods. Among the available gene delivery vectors, adeno-associated viral vectors (AAV) have proven to be highly efficient. Six AAV-based gene therapies have received approval to date, with five recognized by the US FDA, the most recent in June 2023. Concurrently, numerous AAV-based therapies are undergoing assessment in various clinical trials. The trend shows a staggering 30% growth rate in clinical trials evaluating AAV-based gene therapy in recent years, with over 50 trials expected to conclude within the next three years.

To meet this rising demand, nearly 100 companies worldwide have emerged, focusing on AAV-based gene therapy development and manufacturing. Many of these entities offer sophisticated AAV technology platforms capable of producing adeno-associated viral vectors and related therapies across various operational scales, from small to large. The market trajectory for AAV-based gene therapy developers is expected to experience strong growth in the forecast period. This trajectory will be driven by collaborative support from AAV manufacturing companies and providers of advanced AAV technology platforms. The widespread recognition and adoption of AAV vectors as a safe and effective gene therapy delivery option are key factors fueling this promising market outlook.

Report Coverage
 The report conducts an analysis of the AAV vectors market, examining factors such as therapy type, gene delivery methods, therapeutic targets, applications, operational scale, and geographical regions.
 It evaluates market growth influencers like drivers, restraints, opportunities, and challenges.
 Assessment of potential advantages, barriers, and competitive landscape for leading market players is provided.
 Revenue forecasts for market segments are presented across six major regions.
 A concise overview outlines the current state of the adeno-associated viral vectors market and its expected evolution in the medium to long term.
 Comprehensive discussion covers structural design, life cycle dynamics, and applications of adeno-associated viral vectors, concluding with an analysis of their inherent advantages and challenges.
 Detailed examination of the AAV-based gene therapy market includes developmental phases, therapeutic areas, targeted genes, therapy types, delivery methods, administration routes, and special drug designations.
 Examination of companies involved in AAV manufacturing encompasses establishment details, company size, headquarters, manufactured products, facility locations, manufacturing types, operational scale, and application areas.
 Review of technologies offered by companies engaged in the AAV market categorized by types, operational scale, application areas, and identification of prominent market players.
 Detailed profiles of marketed and advanced-stage AAV-based gene therapies cover development timelines, current status, mechanisms of action, associated AAV technologies, patent portfolios, dosage specifics, manufacturing details, and developer company information.
 Tabulated profiles feature select AAV manufacturing companies, including overviews, financial performance (if available), vector manufacturing capabilities, and future outlook.
 Analysis of company competitiveness in AAV manufacturing across regions utilizing a four-dimensional bubble representation considering supplier strength, manufacturing capabilities, service scope, and company size.
 In-depth assessment of AAV vector technology platforms considering supplier strength, technology purpose, operational scale, and application areas.
 Examination of completed, ongoing, and planned clinical trials, assessing parameters such as trial registration year, phase, therapeutic area, geography, sponsors, treatment sites, and enrolled patient populations.
 Evaluation of collaborations and partnerships since 2017 focused on AAV manufacturing, examining partnership types, therapeutic areas, partner types, and regional distributions.
 Insights into potential partnerships with AAV and gene therapy product manufacturers, considering developer strength, product portfolio, therapeutic focus, and pipeline strength.
 Comprehensive analysis of patents filed/granted for AAV-based therapies since 2017, including patent types, publication years, regional applicability, industry leaders in patent filings, and patent valuation.
 Analysis of start-ups developing AAV-based gene therapy, evaluating their developmental stages, patents, partnerships, and key indicators.
 Detailed analysis highlighting factors for AAV-based gene therapy developers to consider when deciding between in-house manufacturing or engaging Contract Manufacturing Organizations (CMOs), considering parameters for small, mid-sized, and large companies.

Key Market Companies
 Abeona Therapeutics
 Aldevron (Acquired by Danaher)
 Oxford BioMedica
 Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
 WuXi AppTec
 YPOSKESI

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis社の分野での最新刊レポート

最新刊レポートはありません。

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis社の分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?